Allurion Technologies (NYSE:ALUR) Given Buy Rating at Roth Mkm

Roth Mkm reiterated their buy rating on shares of Allurion Technologies (NYSE:ALUR) in a report published on Friday,Benzinga reports. They currently have a $16.00 price objective on the stock.

Separately, Chardan Capital reiterated a “neutral” rating and set a $2.50 price objective on shares of Allurion Technologies in a report on Friday.

Allurion Technologies Trading Up 57.7 %

Shares of Allurion Technologies stock opened at $3.60 on Friday. The stock has a 50-day moving average price of $4.00 and a 200 day moving average price of $10.10. The company has a market cap of $17.24 million, a P/E ratio of -0.30 and a beta of -0.59. Allurion Technologies has a 1 year low of $2.15 and a 1 year high of $98.75.

Institutional Trading of Allurion Technologies

An institutional investor recently raised its position in Allurion Technologies stock. Geode Capital Management LLC boosted its position in shares of Allurion Technologies Inc. (NYSE:ALUR) by 40.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 516,330 shares of the company’s stock after acquiring an additional 149,484 shares during the period. Geode Capital Management LLC owned 0.80% of Allurion Technologies worth $317,000 at the end of the most recent quarter. Institutional investors own 21.39% of the company’s stock.

Allurion Technologies Company Profile

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.